Pharmacological modulation of the state of awareness in patients with disorders of consciousness: An overview

Current Pharmaceutical Design

Volumn 20, Issue 26, 2014, Pages 4121-4139

  Mura, Elisa ^a   Pistoia, Francesca ^b,c   Sarà, Marco ^c   Sacco, Simona ^b   Carolei, Antonio ^b   Govoni, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Awakenings; Coma; Consciousness; Drugs; Minimally conscious state; Pharmacology; Vegetative state

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; HISTAMINE; LAMOTRIGINE; METHYLPHENIDATE; NORADRENALIN; OREXIN; PRAMIPEXOLE; SEROTONIN; ZOLPIDEM;

AROUSAL; ASSISTIVE TECHNOLOGY; AWARENESS; BRAIN DEPTH STIMULATION; BRAIN REGION; COMA; CONSCIOUSNESS; CONSCIOUSNESS DISORDER; HUMAN; MUSIC THERAPY; NEUROCHEMISTRY; PRIORITY JOURNAL; REVIEW; SLEEP; STIMULATION ASSISTIVE TECHNOLOGY; TRANSCRANIAL MAGNETIC STIMULATION; WAKEFULNESS; CONSCIOUSNESS DISORDERS; DRUG EFFECTS; PATHOPHYSIOLOGY;

AWARENESS; CONSCIOUSNESS DISORDERS; HUMANS;

EID: 84904761022     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. rd ed. New York: Wiley 1983.
2. Owen AM, Coleman MR. Functional neuroimaging of the vegetative state. Nat Rev Neurosci 2008; 9: 235-43.
3. Sarà M, Pistoia F, Pasqualetti P, Sebastiano F, Onorati P, Rossini PM. Functional isolation within the cerebral cortex in the vegetative state: a nonlinear method to predict clinical outcomes. Neurorehabil Neural Repair 2011; 25: 35-42.
4. Sarà M, Pistoia F. Complexity loss in physiological time series of patients in a vegetative state. Nonlinear Dynamics Psychol Life Sci 2010; 14: 1-13.
5. Sarà M, Sebastiano F, Sacco S, et al. Heart rate non linear dynamics in patients with persistent vegetative state: a preliminary report. Brain Inj 2008; 22: 33-7.
6. Working Party of the Royal College of Physicians. The vegetative state: guidance on diagnosis and management. Clin Med 2003; 3: 249-54.
7. Laureys S. The neural correlate of (un)awareness: lessons from the vegetative state. Trends Cogn Sci 2005; 9: 556-9.
8. Laureys S, Faymonville ME, Luxen A, et al. Restoration of thalamocortical connectivity after recovery from persistent vegetative state. Lancet 2000; 355: 1790-1.
9. Giacino JT, Ashwal S, Childs N, et al. The minimally conscious state: definition and diagnostic criteria. Neurology 2002; 58: 349-53.
10. Tononi G, Cirelli C. Modulation of brain gene expression during sleep and wakefulness: a review of recent findings. Neuropsychopharmacology 2001; 25 (5 Suppl): S28-35.
11. Lu J, Greco MA, Shiromani P, Saper CB. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 2000; 20: 3830-42.
12. Sherin JE, Shiromani PJ, McCarley RW, Saper CB. Activation of ventrolateral preoptic neurons during sleep. Science 1996; 271: 216-9.
13. Sherin JE, Elmquist JK, Torrealba F, Saper CB. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998; 18: 4705-21.
14. Wada H, Inagaki N, Yamatodani A, Watanabe T. Is the histaminergic neuron system a regulatory center for whole-brain activity? Trends Neurosci 1991; 14: 415-8.
15. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-63.
16. Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of Sleep and Wakefulness. Sleep Med Clin 2010; 5: 513-28.
17. Hallanger AE, Levey AI, Lee HJ, Rye DB, Wainer BH. The origins of cholinergic and other subcortical afferents to the thalamus in the rat. J Comp Neurol 1987; 262: 105-24.
18. Satoh K, Fibiger HC. Cholinergic neurons of the laterodorsal tegmental nucleus: efferent and afferent connections. J Comp Neurol 1986; 253: 277-302.
19. Saint-Mleux B, Eggermann E, Bisetti A, et al. Nicotinic enhancement of the noradrenergic inhibition of sleep-promoting neurons in the ventrolateral preoptic area. J Neurosci 2004; 24: 63-7.
20. Hasselmo ME, Bower JM. Acetylcholine and memory. Trends Neurosci 1993; 16: 218-22.
21. Petit D, Gagnon JF, Fantini ML, Ferini-Strambi L, Montplaisir J. Sleep and quantitative EEG in neurodegenerative disorders. J Psychosom Res 2004; 56: 487-96.
22. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981; 1: 876-86.
23. Schwartz JR, Roth T. Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol 2008; 6: 367-78.
24. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007; 11: 113-33.
25. Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000; 23: 185-215.
26. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004; 27: 1181-94.
27. McGinty DJ, Harper RM. Dorsal raphe neurons: depression of firing during sleep. Brain Res 1976; 101: 569e75.
28. Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev 2011; 15: 269-81.
29. Takahashi K, Lin JS, Sakai K. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J Neurosci 2006; 26: 10292-8.
30. Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev 2011; 15: 65-74.
31. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
32. Yoshida K, McCormack S, España RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol 2006; 494: 845-61.
33. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001; 98: 9965-70.
34. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8: 171-81.
35. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345-54.
36. Huang ZL, Urade Y, Hayaishi O. The role of adenosine in the regulation of sleep. Curr Top Med Chem 2011; 11: 1047-57.
37. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001; 42 (Suppl 3): 8-12.
38. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron 2010; 68: 1023-42.
39. Yamaguchi M, Calvert JW, Kusaka G, Zhang JH. One-stage anterior approach for four-vessel occlusion in rat. Stroke 2005; 36: 2212-4.
40. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. Nat Rev Neurosci 2013; 14: 128-42.
41. Wilhelm MJ, Pratschke J, Laskowski IA, Paz DM, Tilney NL. Brain death and its impact on the donor heart-lessons from animal models. J Heart Lung Transplant 2000; 19: 414-8.
42. Bogen JE. On the neurophysiology of consciousness: I. An Overview. Conscious Cogn 1995; 4: 52-62.
43. Huynh F, Mabasa VH, Ensom MH. A critical review: does thiopental continuous infusion warrant therapeutic drug monitoring in the critical care population? Ther Drug Monit 2009; 31: 153-69.
44. Stover JF, Pleines UE, Morganti-Kossmann MC, Stocker R, Kossmann T. Thiopental attenuates energetic impairment but fails to normalize cerebrospinal fluid glutamate in brain-injured patients. Crit Care Med 1999; 27: 1351-7.
45. Statler KD, Alexander H, Vagni V, et al. Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats. J Neurotrauma 2006; 23: 97-108.
46. Murphy M, Bruno MA, Riedner BA, et al. Propofol anesthesia and sleep: a high-density EEG study. Sleep 2011; 34: 283-91A.
47. Boly M, Moran R, Murphy M, et al. Connectivity changes underlying spectral EEG changes during propofol-induced loss of consciousness. J Neurosci 2012; 32: 7082-90.
48. Imas OA, Ropella KM, Wood JD, Hudetz AG. Isoflurane disrupts anterio-posterior phase synchronization of flash-induced field potentials in the rat. Neurosci Lett 2006; 402: 216-21.
49. Boly M, Garrido MI, Gosseries O, et al. Preserved feedforward but impaired top-down processes in the vegetative state. Science 2011; 332: 858-62.
50. Kroeger D, Amzica F. Hypersensitivity of the anesthesia-induced comatose brain. J Neurosci 2009; 27: 10597-607.
51. Machado C, Korein J, Aubert E, et al. Recognizing a mother's voice in the persistent vegetative state. Clin EEG Neurosci 2007; 38: 124-6.
52. Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J 2000; 90: 68-72.
53. Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation 2006; 21: 23-8.
54. Sarà M, Sacco S, Cipolla F, et al. An unexpected recovery from permanent vegetative state. Brain Inj 2007; 21: 101-3.
55. Sarà M, Pistoia F, Mura E, Onorati P, Govoni S. Intrathecal baclofen in patients with persistent vegetative state: two hypotheses. Arch Phys Med Rehabil 2009; 90: 1245-9.
56. Meythaler JM, Depalma L, Devivo MJ, Guin-Renfroe S, Novack TA. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2001; 15: 321-31.
57. Schnakers C, Hustinx R, Vandewalle G, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry 2008; 79: 225-7.
58. Wheaton P, Mathias JL, Vink R. Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis. J Clin Psychopharmacol 2009; 29: 468-77.
59. Pistoia F, Mura E, Govoni S, Fini M, Sarà M. Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs? CNS Drugs 2010; 24: 625-38.
60. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995; 26: 2254-9.
61. Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol 2008; 21: 639-43.
62. Whyte J, Hart T, Vaccaro M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil 2004; 83: 401-20.
63. Worzniak M, Fetters MD, Comfort M. Methylphenidate in the treatment of coma. J Fam Pract 1997; 44: 495-8.
64. Moein H, Khalili HA, Keramatian K. Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin Neurol Neurosurg 2006; 108: 539-42.
65. Kim YW, Shin JC, An YS. Effects of methylphenidate on cerebral glucose metabolism in patients with impaired consciousness after acquired brain injury. Clin Neuropharmacol 2009; 2: 335-9.
66. Wroblewski B, Glenn MB, Cornblatt R, Joseph AB, Suduikis S. Protriptyline as an alternative stimulant medication in patients with brain injury: a series of case reports. Brain Inj 1993; 7:353-62.
67. Reinhard DL, Whyte J, Sandel ME. Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil 1996; 77: 80-3.
68. Mysiw WJ, Jackson RD, Corrigan JD. Amitriptyline for posttraumatic agitation. Am J Phys Med Rehabil 1988; 67: 29-33.
69. Jackson RD, Corrigan JD, Arnett JA. Amitriptyline for agitation in head injury. Arch Phys Med Rehabil 1985; 66: 180-1.
70. Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature 2004; 430: 78-81.
71. Tononi G, Cirelli C. Sleep and synaptic homeostasis: a hypothesis. Brain Res Bull 2003; 62: 143-50.
72. D'Aleo G, Saltuari L, Gerstenbrand F, Bramanti P. Sleep in the last remission stages of vegetative state of traumatic nature. Funct Neurol 1994; 9: 189-92.
73. Isono M, Wakabayashi Y, Fujiki MM, Kamida T, Kobayashi H. Sleep cycle in patients in a state of permanent unconsciousness. Brain Inj 2002; 16: 705-12.
74. Lanni C, Govoni S, Lucchelli A, Boselli C. Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 2009; 66: 2985-3008.
75. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17: 300-13.
76. Haig AJ, Ruess JM. Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/ carbidopa). Arch Phys Med Rehabil 1990; 71: 1081-3.
77. Krimchansky BZ, Keren O, Sazbon L, Groswasser Z. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Inj 2004; 18: 1099-105.
78. Matsuda W, Matsumura A, Komatsu Y, Yanaka K, Nose T. Awakenings from persistent vegetative state: report of three cases with parkinsonism and brain stem lesions on MRI. J Neurol Neurosurg Psychiatry 2003; 74: 1571-3.
79. Matsuda W, Komatsu Y, Yanaka K, Matsumura A. Levodopa treatment for patients in persistent vegetative or minimally conscious states. Neuropsychol Rehabil 2005; 15: 414-27.
80. Ugoya SO, Akinyemi RO. The place of L-dopa/carbidopa in persistent vegetative state. Clin Neuropharmacol 2010; 33: 279-84.
81. Patrick PD, Buck ML, Conaway MR, Blackman JA. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj 2003; 17: 497-506.
82. Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil 2001; 82: 311-5.
83. Fridman EA, Calvar J, Bonetto M, et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj 2009; 23: 172-7.
84. Fridman EA, Krimchansky BZ, Bonetto M, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj 2010; 24: 636-41.
85. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003467.
86. Horiguchi J, Inami Y, Shoda T. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 1990; 13: 84-8.
87. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994; 8: 709-18.
88. Zafonte RD, Watanabe T, Mann NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj 1998; 12: 617-21.
89. McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil 2009; 88: 525-32.
90. Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012; 366: 819-26.
91. Kraus MF, Smith GS, Butters M, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj 2005; 19: 471-9.
92. Rogòz Z, Skuza G, Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep 2008; 60: 817-26.
93. Dario A, Pisani R, Sangiorgi S, Pessina F, Tomei G. Relationship between intrathecal baclofen and the central nervous system. Acta Neurochir Suppl 2007; 97: 461-4.
94. Taira T, Hori T. Intrathecal Baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl 2007; 97: 227-9.
95. Hoarau X, Richer E, Dehail P, Cuny E. Comparison of long-term outcomes of patients with severe traumatic or hypoxic brain injuries treated with intrathecal baclofen therapy for dysautonomia. Brain Inj 2012; 26: 1451-63.
96. Lombardi F, Gatta G, Sacco S, Muratori A, Carolei A. The Italian version of the Coma Recovery Scale-Revised (CRS-R). Funct Neurol 2007; 22: 47-61.
97. Sacco S, Altobelli E, Pistarini C, Cerone D, Cazzulani B, Carolei A. Validation of the Italian version of the Coma Recovery ScaleRevised (CRS-R). Brain Inj 2011; 25(5): 488-95.
98. Whyte J, Katz D, Long D, et al. Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study. Arch Phys Med Rehabil 2005; 86: 453-62.
99. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler R. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-73.
100. Advancing research in Basic Science and Mathematics. http://sfari.org/news-and-opinion/in-brief/2012/molecular-mechanisms-drug-corrects-excitable-mouse-brains, last accessed June 14, 2103.
101. Markram K, Markram H. The intense world theory-a unifying theory of the neurobiology of autism. Front Hum Neurosci 2010; 4: 224.
102. Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature 1981; 290: 149-52.
103. Jones EG. Thalamic organization and function after Cajal. Prog Brain Res 2002; 136: 333-57.
104. Showalter PE, Kimmel DN. Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine. Brain Inj 2000; 14: 997-1001.
105. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997; 12(Suppl 1): S2-9.
106. Calabresi P, Centonze D, Cupini LM, Costa C, Pisani F, Bernardi G. Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitrostudies. Neurobiol Dis 2003; 12: 82-8.
107. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23: 484-95.
108. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29: 142-53.
109. Shames JL, Ring H. Transient reversal of anoxic brain injury related minimally conscious state after Zolpidem administration: a case report. Arch Phys Med Rehabil 2008; 89: 386-8.
110. Machado C, Estévez M, Pérez-Nellar J, et al. Autonomic, EEG, and behavioral arousal signs in a PVS case after Zolpidem intake. Can J Neurol Sci 2011; 38: 341-4.
111. Du B, Shan A, Zhang Y, Zhong X, Chen D, Cai K. Zolpidem Arouses Patients in Vegetative State After Brain Injury: Quantitative Evaluation and Indications. Am J Med Sci 2013 Mar 4. [Epub ahead of print]
112. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 18(Suppl 1): 9-15.
113. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002; 451: 103-10.
114. Clauss RP. Neurotransmitters in coma, vegetative and minimally conscious states, pharmacological interventions. Med Hypotheses 2010; 75: 287-90.
115. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med 2004; 350: 949-50.
116. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med 2004; 351: 511-2.
117. Hall SD, Yamawaki N, Fisher AE, Clauss RP, Woodhall GL, Stanford IM. GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke--a case report. Clin Neurophysiol 2010; 121: 549-55.
118. Singh R, McDonald C, Dawson K, et al. Zolpidem in a minimally conscious state. Brain Inj 2008; 22: 103-6.
119. Lo YL, Tan EK, Ratnagopal P, Chan LL, Tan TE. Zolpidem and its effects on hypoxic encephalopathy. Ann Neurol 2008; 64: 477-8.
120. Whyte J, Myers R. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil 2009; 88: 410-8.
121. Snyman N, Egan JR, London K, et al. Zolpidem for persistent vegetative state--a placebo-controlled trial in pediatrics. Neuropediatrics 2010; 41: 223-7.
122. Verweij BH, Amelink GJ, Muizelaar JP. Current concepts of cerebral oxygen transport and energy metabolism after severe traumatic brain injury. Prog Brain Res 2007; 161: 111-24.
123. Wu HM, Huang SC, Hattori N, et al. Subcortical white matter metabolic changes remote from focal hemorrhagic lesions suggest diffuse injury after human traumatic brain injury. Neurosurgery 2004; 55: 1306-15; discussio 1316-7.
124. Mathiesen C, Caesar K, Thomsen K, et al. Activity-dependent increases in local oxygen consumption correlate with postsynaptic currents in the mouse cerebellum in vivo. J Neurosci 2011; 31: 18327-37.
125. Hattori N, Huang SC, Wu HM, et al. Correlation of regional metabolic rates of glucose with glasgow coma scale after traumatic brain injury. J Nucl Med 2003; 44: 1709-16.
126. Prajapati KD, Sharma SS, Roy N. Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci 2011; 22: 355-63.
127. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012; 18: 1812-9.
128. Wu HM, Huang SC, Hattori N, et al. Selective metabolic reduction in gray matter acutely following human traumatic brain injury. J Neurotrauma 2004; 21: 149-61.
129. Aquilani R, Boselli M, Boschi F, et al. Branched-chain amino acids may improve recovery from a vegetative or minimally conscious state in patients with traumatic brain injury: a pilot study. Arch Phys Med Rehabil 2008; 89: 1642-7.
130. Fellerhoff B, Laumbacher B, Wank R. Responsiveness of a patient in a persistent vegetative state after a coma to weekly injections of autologous activated immune cells: a case report. J Med Case Rep 2012; 6: 6.
131. Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162: 6303-6.
132. Vega JA, García-Suárez O, Hannestad J, Pérez-Pérez M, Germanà A. Neurotrophins and the immune system. J Anat 2003; 203: 1-19.
133. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 2012; 308: 1993-2000.
134. Lancioni GE, Bosco A, Belardinelli MO, Singh NN, O'Reilly MF, Sigafoos J. An overview of intervention options for promoting adaptive behavior of persons with acquired brain injury and minimally conscious state. Res Dev Disabil 2010; 31: 1121-34.
135. Shirota Y, Ohtsu H, Hamada M, Enomoto H, Ugawa Y. Research Committee on rTMS Treatment of Parkinson's Disease. Supplementary motor area stimulation for Parkinson disease: A randomized controlled study. Neurology 2013; 80: 1400-5.
136. Okun MS. Deep-brain stimulation for Parkinson's disease. N Engl J Med 2012; 367: 1529-38.
137. Louise-Bender Pape T, Rosenow J, Lewis G, et al. Repetitive transcranial magnetic stimulation-associated neurobehavioral gains during coma recovery. Brain Stimul 2009; 2: 22-35.
138. Yamamoto T, Katayama Y, Obuchi T, Kobayashi K, Oshima H, Fukaya C. Deep Brain Stimulation and Spinal Cord Stimulation for Vegetative State and Minimally Conscious State. World Neurosurg 2012 [Epub ahead of print].
139. Schiff ND, Giacino JT, Kalmar K, et al. Behavioural improvements with thalamic stimulation after severe traumatic brain injury. Nature 2007; 448: 600-3.
140. Pistoia F, Sacco S, Carolei A, Sarà M. Corticomotor Facilitation in Vegetative State: Results of a Pilot Study. Arch Phys Med Rehabil 2013 Feb 4 [Epub ahead of print]
141. Canedo A, Grix MC, Nicoletti J. An analysis of assessment instruments for the minimally responsive patient (MRP): clinical observations. Brain Inj 2002; 16: 453-61.
142. Barreca S, Velikonja D, Brown L, Williams L, Davis L, Sigouin CS. Evaluation of the effectiveness of two clinical training procedures to elicit yes/no responses from patients with a severe acquired brain injury: a randomized single-subject design. Brain Inj 2003; 17: 1065-75.
143. Seibert PS, Fee L, Basom J, Zimmerman C. Music and the brain: the impact of music on an oboist's fight for recovery. Brain Inj 2000; 14: 295-302.
144. Formisano R, Vinicola V, Penta F, Matteis M, Brunelli S, Weckel JW. Active music therapy in the rehabilitation of severe brain injured patients during coma recovery. Ann Ist Super Sanita 2001; 37: 627-30.
145. Magee WL. Music therapy with patients in low awareness states: approaches to assessment and treatment in multidisciplinary care. Neuropsychol Rehabil 2005; 15: 522-36.
146. Clifton GL, Valadka A, Zygun D, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol 2011; 10: 131-9.
147. Sarà M, Pistoia F. Defining consciousness: lessons from patients and modern techniques. J Neurotrauma 2010; 27: 771-3.
148. Whyte J. Treatments to enhance recovery from the vegetative and minimally conscious states: ethical issues surrounding efficacy studies. Am J Phys Med Rehabil 2007; 86: 86-92.
149. Sarà M, Pistoia F. Bedside detection of awareness in the vegetative state. Lancet 2012; 379: 1702-3.
150. Formisano R, Pistoia F, Sarà M. Disorders of consciousness: a taxonomy to be changed? Brain Inj 2011; 25: 638-9.
151. Pistoia F, Sarà M. Is there a cartesian renaissance of the mind or is it time for a new taxonomy for low responsive states? J Neurotrauma 2012; 29: 2328-31.
152. Babiloni C, Pistoia F, Sarà M, et al. Resting state eyes-closed cortical rhythms in patients with locked-in-syndrome: an EEG study. Clin Neurophysiol 2010; 121: 1816-24.
153. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-59.